<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Approach to the selection of Fabry-specific therapy in patients with Fabry disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Approach to the selection of Fabry-specific therapy in patients with Fabry disease</h1>
<div class="graphic"><div class="figure"><div class="ttl">Approach to the selection of Fabry-specific therapy in patients with Fabry disease</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_footnotes"><p><em>GLA</em>: galactosidase alpha; eGFR: estimated glomerular filtration rate; ERT: enzyme replacement therapy.</p>
<p>* Indications vary depending on the patient's clinical phenotype. Refer to UpToDate content on indications to initiate Fabry-specific therapy in patients with Fabry disease.</p>
<p>¶ <em>GLA</em> gene variants that are likely to result in a substantial increase in enzyme level may be candidates for migalastat monotherapy instead of ERT. An online tool to determine whether a specific patient's <em>GLA</em> gene variant is amenable to migalastat therapy is available at https://www.galafoldamenabilitytable.us.</p>
<p>Δ Refer to UpToDate content on monitoring for disease progression in patients with Fabry disease.</p>
<p>◊ Migalastat has not yet been approved in the United States for use in children &lt;18 years of age but is approved in the European Union for children ≥12 years old. In addition, migalastat should not be used in patients with an eGFR &lt;30 mL/min/1.73 m<sup>2</sup>, as such patients were excluded from the clinical trials evaluating its efficacy and safety.</p>
§ Available formulations of ERT include agalsidase alfa, agalsidase beta, and pegunigalsidase alfa (for patients &gt;18 years old). Refer to UpToDate content for information regarding dosing and administration of ERT.</div><div id="graphicVersion">Graphic 139011 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
